b2m(1)-specific guide rna Search Results


b2m(1)-specific guide rna  (GenScript corporation)
90
GenScript corporation b2m(1)-specific guide rna
B2m(1) Specific Guide Rna, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b2m(1)-specific guide rna/product/GenScript corporation
Average 90 stars, based on 1 article reviews
b2m(1)-specific guide rna - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
guide rna (gagtagcgcgagca cagcta)  (GenScript corporation)
90
GenScript corporation guide rna (gagtagcgcgagca cagcta)
Guide Rna (Gagtagcgcgagca Cagcta), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/guide rna (gagtagcgcgagca cagcta)/product/GenScript corporation
Average 90 stars, based on 1 article reviews
guide rna (gagtagcgcgagca cagcta) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
cas9  (KACTUS Bio)
90
KACTUS Bio cas9
Cas9, supplied by KACTUS Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cas9/product/KACTUS Bio
Average 90 stars, based on 1 article reviews
cas9 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
b2m(2)-specific guide rna  (GenScript corporation)
90
GenScript corporation b2m(2)-specific guide rna
B2m(2) Specific Guide Rna, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b2m(2)-specific guide rna/product/GenScript corporation
Average 90 stars, based on 1 article reviews
b2m(2)-specific guide rna - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
trac-specific guide rna  (GenScript corporation)
90
GenScript corporation trac-specific guide rna
Trac Specific Guide Rna, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/trac-specific guide rna/product/GenScript corporation
Average 90 stars, based on 1 article reviews
trac-specific guide rna - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
cbe3  (GenScript corporation)
90
GenScript corporation cbe3
Cbe3, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cbe3/product/GenScript corporation
Average 90 stars, based on 1 article reviews
cbe3 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
anti-stat3 monoclonal mouse  (Becton Dickinson)
90
Becton Dickinson anti-stat3 monoclonal mouse
Molecular Dissection of <t>ERBB-STAT3</t> Axis in DFTD (A) Western blots of total STAT3, pS-STAT3, and pY-STAT3 of four DFTD cell lines (T1–T4) and fibroblasts (Fib.). (B) Total protein phosphorylation immunoblots from lysates of four DFTD cell lines (T1–T4) and fibroblasts (Fib.) using a global anti-pY monoclonal antibody (4G10) in different input amounts. (C) Western blots of total ERK1/2 and pT/Y-ERK1/2 of four DFTD cell lines (T1–T4) and fibroblasts (Fib.). (D) Representative images of IHC for total STAT3, pS-STAT3, pY-STAT3, and PRX in primary tumor and peripheral nerve biopsy on serial consecutive sections and quantification of total STAT3, pS-STAT3, and pY-STAT3 in tumor biopsies, adjacent tissue, and peripheral nerve tissue. Dotted rectangles indicate magnified areas. Scale bars, 200 and 25 μm. (E) Five-point dose-response curve of cell lines to the STAT3 inhibitor PG-S3-009 with DFTD and fibroblast cell lines. (F) Structure of DR-1-55. (G) Five-point dose-response curve of cell lines to the STAT3 inhibitor DR-1-55 with DFTD and fibroblast cell lines. (H) DFTD cells treated with 2 μM PG-S3-009, 4 μM DR-1-55, or DMSO as control. Twenty-four hours after treatment, expression of ERBB2 and ERBB3 was measured by real-time PCR (n = 3 replicates). (I) Western blots of total STAT3, pS-STAT3, and pY-STAT3 upon treatment with the ERBB inhibitors lapatinib (1 μM) and sapitinib (1 μM). Statistical significance was calculated by (D and H) unpaired t test. Graphs represent the mean ± SEM. See also <xref ref-type=Figure S4 . " width="250" height="auto" />
Anti Stat3 Monoclonal Mouse, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-stat3 monoclonal mouse/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-stat3 monoclonal mouse - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
anti phospho her3 erbb3 y1289 monoclonal rabbit  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc anti phospho her3 erbb3 y1289 monoclonal rabbit

Anti Phospho Her3 Erbb3 Y1289 Monoclonal Rabbit, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti phospho her3 erbb3 y1289 monoclonal rabbit/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
anti phospho her3 erbb3 y1289 monoclonal rabbit - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier

Image Search Results


Molecular Dissection of ERBB-STAT3 Axis in DFTD (A) Western blots of total STAT3, pS-STAT3, and pY-STAT3 of four DFTD cell lines (T1–T4) and fibroblasts (Fib.). (B) Total protein phosphorylation immunoblots from lysates of four DFTD cell lines (T1–T4) and fibroblasts (Fib.) using a global anti-pY monoclonal antibody (4G10) in different input amounts. (C) Western blots of total ERK1/2 and pT/Y-ERK1/2 of four DFTD cell lines (T1–T4) and fibroblasts (Fib.). (D) Representative images of IHC for total STAT3, pS-STAT3, pY-STAT3, and PRX in primary tumor and peripheral nerve biopsy on serial consecutive sections and quantification of total STAT3, pS-STAT3, and pY-STAT3 in tumor biopsies, adjacent tissue, and peripheral nerve tissue. Dotted rectangles indicate magnified areas. Scale bars, 200 and 25 μm. (E) Five-point dose-response curve of cell lines to the STAT3 inhibitor PG-S3-009 with DFTD and fibroblast cell lines. (F) Structure of DR-1-55. (G) Five-point dose-response curve of cell lines to the STAT3 inhibitor DR-1-55 with DFTD and fibroblast cell lines. (H) DFTD cells treated with 2 μM PG-S3-009, 4 μM DR-1-55, or DMSO as control. Twenty-four hours after treatment, expression of ERBB2 and ERBB3 was measured by real-time PCR (n = 3 replicates). (I) Western blots of total STAT3, pS-STAT3, and pY-STAT3 upon treatment with the ERBB inhibitors lapatinib (1 μM) and sapitinib (1 μM). Statistical significance was calculated by (D and H) unpaired t test. Graphs represent the mean ± SEM. See also <xref ref-type=Figure S4 . " width="100%" height="100%">

Journal: Cancer Cell

Article Title: The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

doi: 10.1016/j.ccell.2018.11.018

Figure Lengend Snippet: Molecular Dissection of ERBB-STAT3 Axis in DFTD (A) Western blots of total STAT3, pS-STAT3, and pY-STAT3 of four DFTD cell lines (T1–T4) and fibroblasts (Fib.). (B) Total protein phosphorylation immunoblots from lysates of four DFTD cell lines (T1–T4) and fibroblasts (Fib.) using a global anti-pY monoclonal antibody (4G10) in different input amounts. (C) Western blots of total ERK1/2 and pT/Y-ERK1/2 of four DFTD cell lines (T1–T4) and fibroblasts (Fib.). (D) Representative images of IHC for total STAT3, pS-STAT3, pY-STAT3, and PRX in primary tumor and peripheral nerve biopsy on serial consecutive sections and quantification of total STAT3, pS-STAT3, and pY-STAT3 in tumor biopsies, adjacent tissue, and peripheral nerve tissue. Dotted rectangles indicate magnified areas. Scale bars, 200 and 25 μm. (E) Five-point dose-response curve of cell lines to the STAT3 inhibitor PG-S3-009 with DFTD and fibroblast cell lines. (F) Structure of DR-1-55. (G) Five-point dose-response curve of cell lines to the STAT3 inhibitor DR-1-55 with DFTD and fibroblast cell lines. (H) DFTD cells treated with 2 μM PG-S3-009, 4 μM DR-1-55, or DMSO as control. Twenty-four hours after treatment, expression of ERBB2 and ERBB3 was measured by real-time PCR (n = 3 replicates). (I) Western blots of total STAT3, pS-STAT3, and pY-STAT3 upon treatment with the ERBB inhibitors lapatinib (1 μM) and sapitinib (1 μM). Statistical significance was calculated by (D and H) unpaired t test. Graphs represent the mean ± SEM. See also Figure S4 .

Article Snippet: Nitrocellulose membranes (0.45 μm Amersham Protran 10600002, GE Healthcare, Buckinghamshire, UK) were incubated with the following antibodies in the dilution as indicated (see also ): specific anti-phospho-STAT3 (Y705) polyclonal rabbit (1:1000; 9131; Cell Signaling Technology, Cambridge, UK), anti-STAT3 monoclonal mouse (1:1000; 610189; BD Biosciences, Franklin Lakes, NJ, USA) or (9139; Cell Signaling; 1:1000), anti-phospho-STAT3 (S727) polyclonal rabbit (1:1000; 9134; Cell Signaling Technology, Cambridge, UK), anti-STAT1 (rabbit; 9172; Cell Signaling; 1:1000), anti-phospho-STAT1 (Y701) monoclonal rabbit (1:1000; 9167; Cell Signaling Technology), anti-EGFL8 polyclonal rabbit (1:1000; ab58650; Abcam, Cambridge, UK), anti-phospho-EGFR (Y1068) monoclonal rabbit (1:1000; 3777; Cell Signaling Technology), anti-EGFR monoclonal rabbit (1:1000; sc-373746; Santa Cruz, Dallas, TX, USA), anti-phospho-HER2/ERBB2 (Y1221/1222) monoclonal rabbit (1:1000; 2243; Cell Signaling Technology), anti-ERBB2 monoclonal mouse (1:1000, sc-7301; Santa Cruz Biotechnology), anti-phospho-HER3/ERBB3 (Y1289) monoclonal rabbit (1:1000; 2842; Cell Signaling Technology), anti-HER3/ERBB3 monoclonal rabbit (1:1000; 12708; Cell Signaling Technology), anti-HSC70 monoclonal mouse (1:1000; sc-7298; Santa Cruz), anti-TRIM28 polyclonal rabbit (1:1000; ABE1859; Millipore); anti-ERK1/2 monoclonal rabbit (1:1000; 4695; Cell Signaling Technology, Cambridge, UK), anti-phospho-ERK1/2 (T202/Y204) monoclonal rabbit (1:1000; 4370; Cell Signaling Technology, Cambridge, UK), anti-pY (4G10; Merck Millipore; 1:1000), anti-SOCS (1:1000; 3950; Cell Signaling Technology, Cambridge, UK), anti-B2M (1:1000; ( )), ECL anti-rabbit IgG (NA934V) or anti-mouse (NA931) HRP (1:10000; GE Healthcare, Buckinghamshire, UK).

Techniques: Dissection, Western Blot, Expressing, Real-time Polymerase Chain Reaction

Blockade of ERBB Induces MHC Class I Gene Expression (A) DFTD tumor cell line T1 was treated with recombinant interferon-γ (rIFN-γ) and/or 1 μM sapitinib. Control cells were treated with solvents. Forty-eight hours after treatment, expression of B2M , SAHA-UC , STAT1 , and STAT3 were measured by real-time PCR (n = 3 replicates). (B) Reciprocal co-immunoprecipitation of STAT3 and STAT1 followed by western blots for STAT3 and STAT1 in DFTD tumor cell line (T1), fibroblasts, and human HT29 colon cancer cells as control. (C and D) Tumor volume (C) and tumor weight (D) of DFTD tumor cell line T1 transplanted into NSG mice and treated with either vehicle or 50 mg/kg sapitinib once daily (bilateral tumors, n = 5 mice per group). One out of two representative experiments is shown. (E) H&E and IHC analyses for total STAT3, pS-STAT3, pY-STAT3, Ki67, and Cleaved Caspase 3 of tumor tissues. Pictures shown are from contiguous sections. Dotted rectangles indicate magnified areas. Quantification of total STAT3, pS-STAT3, pY-STAT3, Ki67, and Cleaved Caspase 3. Scale bars, 200 and 25 μm. (F) Western blots for total STAT3, pY-STAT3, pS-STAT3, and STAT1 from representative xenograft tumors. (G) Expression of B2M and STAT3 by real-time PCR from xenograft tumor tissue. Statistical significance was calculated by (A) one-way or (C) two-way ANOVA with Bonferroni correction or (D, E, and G) unpaired t test. Graphs represent the mean ± SEM. See also and .

Journal: Cancer Cell

Article Title: The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

doi: 10.1016/j.ccell.2018.11.018

Figure Lengend Snippet: Blockade of ERBB Induces MHC Class I Gene Expression (A) DFTD tumor cell line T1 was treated with recombinant interferon-γ (rIFN-γ) and/or 1 μM sapitinib. Control cells were treated with solvents. Forty-eight hours after treatment, expression of B2M , SAHA-UC , STAT1 , and STAT3 were measured by real-time PCR (n = 3 replicates). (B) Reciprocal co-immunoprecipitation of STAT3 and STAT1 followed by western blots for STAT3 and STAT1 in DFTD tumor cell line (T1), fibroblasts, and human HT29 colon cancer cells as control. (C and D) Tumor volume (C) and tumor weight (D) of DFTD tumor cell line T1 transplanted into NSG mice and treated with either vehicle or 50 mg/kg sapitinib once daily (bilateral tumors, n = 5 mice per group). One out of two representative experiments is shown. (E) H&E and IHC analyses for total STAT3, pS-STAT3, pY-STAT3, Ki67, and Cleaved Caspase 3 of tumor tissues. Pictures shown are from contiguous sections. Dotted rectangles indicate magnified areas. Quantification of total STAT3, pS-STAT3, pY-STAT3, Ki67, and Cleaved Caspase 3. Scale bars, 200 and 25 μm. (F) Western blots for total STAT3, pY-STAT3, pS-STAT3, and STAT1 from representative xenograft tumors. (G) Expression of B2M and STAT3 by real-time PCR from xenograft tumor tissue. Statistical significance was calculated by (A) one-way or (C) two-way ANOVA with Bonferroni correction or (D, E, and G) unpaired t test. Graphs represent the mean ± SEM. See also and .

Article Snippet: Nitrocellulose membranes (0.45 μm Amersham Protran 10600002, GE Healthcare, Buckinghamshire, UK) were incubated with the following antibodies in the dilution as indicated (see also ): specific anti-phospho-STAT3 (Y705) polyclonal rabbit (1:1000; 9131; Cell Signaling Technology, Cambridge, UK), anti-STAT3 monoclonal mouse (1:1000; 610189; BD Biosciences, Franklin Lakes, NJ, USA) or (9139; Cell Signaling; 1:1000), anti-phospho-STAT3 (S727) polyclonal rabbit (1:1000; 9134; Cell Signaling Technology, Cambridge, UK), anti-STAT1 (rabbit; 9172; Cell Signaling; 1:1000), anti-phospho-STAT1 (Y701) monoclonal rabbit (1:1000; 9167; Cell Signaling Technology), anti-EGFL8 polyclonal rabbit (1:1000; ab58650; Abcam, Cambridge, UK), anti-phospho-EGFR (Y1068) monoclonal rabbit (1:1000; 3777; Cell Signaling Technology), anti-EGFR monoclonal rabbit (1:1000; sc-373746; Santa Cruz, Dallas, TX, USA), anti-phospho-HER2/ERBB2 (Y1221/1222) monoclonal rabbit (1:1000; 2243; Cell Signaling Technology), anti-ERBB2 monoclonal mouse (1:1000, sc-7301; Santa Cruz Biotechnology), anti-phospho-HER3/ERBB3 (Y1289) monoclonal rabbit (1:1000; 2842; Cell Signaling Technology), anti-HER3/ERBB3 monoclonal rabbit (1:1000; 12708; Cell Signaling Technology), anti-HSC70 monoclonal mouse (1:1000; sc-7298; Santa Cruz), anti-TRIM28 polyclonal rabbit (1:1000; ABE1859; Millipore); anti-ERK1/2 monoclonal rabbit (1:1000; 4695; Cell Signaling Technology, Cambridge, UK), anti-phospho-ERK1/2 (T202/Y204) monoclonal rabbit (1:1000; 4370; Cell Signaling Technology, Cambridge, UK), anti-pY (4G10; Merck Millipore; 1:1000), anti-SOCS (1:1000; 3950; Cell Signaling Technology, Cambridge, UK), anti-B2M (1:1000; ( )), ECL anti-rabbit IgG (NA934V) or anti-mouse (NA931) HRP (1:10000; GE Healthcare, Buckinghamshire, UK).

Techniques: Expressing, Recombinant, Real-time Polymerase Chain Reaction, Immunoprecipitation, Western Blot

Xenograft Model with STAT3 Inhibitor DR-1-55 (A and B) Tumor volume (A) and tumor weight (B) of NSG mice transplanted with DFTD tumor cell line T1 and, 22 days after transplantation, treated with either vehicle or 10 mg/kg DR-1-55 each day (bilateral tumors, n = 5 mice per group). (C) Serum concentration of alanine aminotransferase, aspartate aminotransferase, and blood urea nitrogen. (D) Tumor tissue immunohistochemically stained and quantified for total STAT3, pS-STAT3, pY-STAT3, Ki67, Cleaved Caspase 3, and MMP2. Pictures shown are from contiguous sections. Dotted rectangles indicate magnified areas. Scale bars, 200 and 25 μm. (E) Western blots for total STAT3, pY-STAT3, pS-STAT3, and STAT1 from representative xenograft tumors. (F) Expression of B2M and STAT3 by real-time PCR from xenograft tumor tissue. Statistical significance was calculated by (A) two-way ANOVA with Bonferroni correction or (B–D and F) unpaired t test. Graphs represent the mean ± SEM. See also <xref ref-type=Figure S6 . " width="100%" height="100%">

Journal: Cancer Cell

Article Title: The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

doi: 10.1016/j.ccell.2018.11.018

Figure Lengend Snippet: Xenograft Model with STAT3 Inhibitor DR-1-55 (A and B) Tumor volume (A) and tumor weight (B) of NSG mice transplanted with DFTD tumor cell line T1 and, 22 days after transplantation, treated with either vehicle or 10 mg/kg DR-1-55 each day (bilateral tumors, n = 5 mice per group). (C) Serum concentration of alanine aminotransferase, aspartate aminotransferase, and blood urea nitrogen. (D) Tumor tissue immunohistochemically stained and quantified for total STAT3, pS-STAT3, pY-STAT3, Ki67, Cleaved Caspase 3, and MMP2. Pictures shown are from contiguous sections. Dotted rectangles indicate magnified areas. Scale bars, 200 and 25 μm. (E) Western blots for total STAT3, pY-STAT3, pS-STAT3, and STAT1 from representative xenograft tumors. (F) Expression of B2M and STAT3 by real-time PCR from xenograft tumor tissue. Statistical significance was calculated by (A) two-way ANOVA with Bonferroni correction or (B–D and F) unpaired t test. Graphs represent the mean ± SEM. See also Figure S6 .

Article Snippet: Nitrocellulose membranes (0.45 μm Amersham Protran 10600002, GE Healthcare, Buckinghamshire, UK) were incubated with the following antibodies in the dilution as indicated (see also ): specific anti-phospho-STAT3 (Y705) polyclonal rabbit (1:1000; 9131; Cell Signaling Technology, Cambridge, UK), anti-STAT3 monoclonal mouse (1:1000; 610189; BD Biosciences, Franklin Lakes, NJ, USA) or (9139; Cell Signaling; 1:1000), anti-phospho-STAT3 (S727) polyclonal rabbit (1:1000; 9134; Cell Signaling Technology, Cambridge, UK), anti-STAT1 (rabbit; 9172; Cell Signaling; 1:1000), anti-phospho-STAT1 (Y701) monoclonal rabbit (1:1000; 9167; Cell Signaling Technology), anti-EGFL8 polyclonal rabbit (1:1000; ab58650; Abcam, Cambridge, UK), anti-phospho-EGFR (Y1068) monoclonal rabbit (1:1000; 3777; Cell Signaling Technology), anti-EGFR monoclonal rabbit (1:1000; sc-373746; Santa Cruz, Dallas, TX, USA), anti-phospho-HER2/ERBB2 (Y1221/1222) monoclonal rabbit (1:1000; 2243; Cell Signaling Technology), anti-ERBB2 monoclonal mouse (1:1000, sc-7301; Santa Cruz Biotechnology), anti-phospho-HER3/ERBB3 (Y1289) monoclonal rabbit (1:1000; 2842; Cell Signaling Technology), anti-HER3/ERBB3 monoclonal rabbit (1:1000; 12708; Cell Signaling Technology), anti-HSC70 monoclonal mouse (1:1000; sc-7298; Santa Cruz), anti-TRIM28 polyclonal rabbit (1:1000; ABE1859; Millipore); anti-ERK1/2 monoclonal rabbit (1:1000; 4695; Cell Signaling Technology, Cambridge, UK), anti-phospho-ERK1/2 (T202/Y204) monoclonal rabbit (1:1000; 4370; Cell Signaling Technology, Cambridge, UK), anti-pY (4G10; Merck Millipore; 1:1000), anti-SOCS (1:1000; 3950; Cell Signaling Technology, Cambridge, UK), anti-B2M (1:1000; ( )), ECL anti-rabbit IgG (NA934V) or anti-mouse (NA931) HRP (1:10000; GE Healthcare, Buckinghamshire, UK).

Techniques: Transplantation Assay, Concentration Assay, Staining, Western Blot, Expressing, Real-time Polymerase Chain Reaction

Working Model for the Impact of the ERBB-STAT3 Axis in DFTD (A) Aggressive social interactions in the highly inbred population of Tasmanian devils enabled the rapid spread of DFTD with fatal consequences. The hyperactive ERBB-STAT3 axis induces the expression of downstream metastasis-related genes (i.e., MMP2 ) while suppressing the expression of MHC class I genes (i.e., B2M ). We hypothesize that highly abundant phosphorylated STAT3 protein traps unphosphorylated STAT1 proteins in heterodimers, thereby preventing the transcriptional regulation of STAT1 downstream target genes such as B2M . This may contribute to immune evasion and the known lack of tumor rejection upon horizontal transmission. (B) Interference with the ERBB-STAT3 axis by using either ERBB inhibitors or STAT3 inhibitors results in killing of DFTD tumor cells.

Journal: Cancer Cell

Article Title: The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

doi: 10.1016/j.ccell.2018.11.018

Figure Lengend Snippet: Working Model for the Impact of the ERBB-STAT3 Axis in DFTD (A) Aggressive social interactions in the highly inbred population of Tasmanian devils enabled the rapid spread of DFTD with fatal consequences. The hyperactive ERBB-STAT3 axis induces the expression of downstream metastasis-related genes (i.e., MMP2 ) while suppressing the expression of MHC class I genes (i.e., B2M ). We hypothesize that highly abundant phosphorylated STAT3 protein traps unphosphorylated STAT1 proteins in heterodimers, thereby preventing the transcriptional regulation of STAT1 downstream target genes such as B2M . This may contribute to immune evasion and the known lack of tumor rejection upon horizontal transmission. (B) Interference with the ERBB-STAT3 axis by using either ERBB inhibitors or STAT3 inhibitors results in killing of DFTD tumor cells.

Article Snippet: Nitrocellulose membranes (0.45 μm Amersham Protran 10600002, GE Healthcare, Buckinghamshire, UK) were incubated with the following antibodies in the dilution as indicated (see also ): specific anti-phospho-STAT3 (Y705) polyclonal rabbit (1:1000; 9131; Cell Signaling Technology, Cambridge, UK), anti-STAT3 monoclonal mouse (1:1000; 610189; BD Biosciences, Franklin Lakes, NJ, USA) or (9139; Cell Signaling; 1:1000), anti-phospho-STAT3 (S727) polyclonal rabbit (1:1000; 9134; Cell Signaling Technology, Cambridge, UK), anti-STAT1 (rabbit; 9172; Cell Signaling; 1:1000), anti-phospho-STAT1 (Y701) monoclonal rabbit (1:1000; 9167; Cell Signaling Technology), anti-EGFL8 polyclonal rabbit (1:1000; ab58650; Abcam, Cambridge, UK), anti-phospho-EGFR (Y1068) monoclonal rabbit (1:1000; 3777; Cell Signaling Technology), anti-EGFR monoclonal rabbit (1:1000; sc-373746; Santa Cruz, Dallas, TX, USA), anti-phospho-HER2/ERBB2 (Y1221/1222) monoclonal rabbit (1:1000; 2243; Cell Signaling Technology), anti-ERBB2 monoclonal mouse (1:1000, sc-7301; Santa Cruz Biotechnology), anti-phospho-HER3/ERBB3 (Y1289) monoclonal rabbit (1:1000; 2842; Cell Signaling Technology), anti-HER3/ERBB3 monoclonal rabbit (1:1000; 12708; Cell Signaling Technology), anti-HSC70 monoclonal mouse (1:1000; sc-7298; Santa Cruz), anti-TRIM28 polyclonal rabbit (1:1000; ABE1859; Millipore); anti-ERK1/2 monoclonal rabbit (1:1000; 4695; Cell Signaling Technology, Cambridge, UK), anti-phospho-ERK1/2 (T202/Y204) monoclonal rabbit (1:1000; 4370; Cell Signaling Technology, Cambridge, UK), anti-pY (4G10; Merck Millipore; 1:1000), anti-SOCS (1:1000; 3950; Cell Signaling Technology, Cambridge, UK), anti-B2M (1:1000; ( )), ECL anti-rabbit IgG (NA934V) or anti-mouse (NA931) HRP (1:10000; GE Healthcare, Buckinghamshire, UK).

Techniques: Expressing, Transmission Assay

Journal: Cancer Cell

Article Title: The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

doi: 10.1016/j.ccell.2018.11.018

Figure Lengend Snippet:

Article Snippet: Nitrocellulose membranes (0.45 μm Amersham Protran 10600002, GE Healthcare, Buckinghamshire, UK) were incubated with the following antibodies in the dilution as indicated (see also ): specific anti-phospho-STAT3 (Y705) polyclonal rabbit (1:1000; 9131; Cell Signaling Technology, Cambridge, UK), anti-STAT3 monoclonal mouse (1:1000; 610189; BD Biosciences, Franklin Lakes, NJ, USA) or (9139; Cell Signaling; 1:1000), anti-phospho-STAT3 (S727) polyclonal rabbit (1:1000; 9134; Cell Signaling Technology, Cambridge, UK), anti-STAT1 (rabbit; 9172; Cell Signaling; 1:1000), anti-phospho-STAT1 (Y701) monoclonal rabbit (1:1000; 9167; Cell Signaling Technology), anti-EGFL8 polyclonal rabbit (1:1000; ab58650; Abcam, Cambridge, UK), anti-phospho-EGFR (Y1068) monoclonal rabbit (1:1000; 3777; Cell Signaling Technology), anti-EGFR monoclonal rabbit (1:1000; sc-373746; Santa Cruz, Dallas, TX, USA), anti-phospho-HER2/ERBB2 (Y1221/1222) monoclonal rabbit (1:1000; 2243; Cell Signaling Technology), anti-ERBB2 monoclonal mouse (1:1000, sc-7301; Santa Cruz Biotechnology), anti-phospho-HER3/ERBB3 (Y1289) monoclonal rabbit (1:1000; 2842; Cell Signaling Technology), anti-HER3/ERBB3 monoclonal rabbit (1:1000; 12708; Cell Signaling Technology), anti-HSC70 monoclonal mouse (1:1000; sc-7298; Santa Cruz), anti-TRIM28 polyclonal rabbit (1:1000; ABE1859; Millipore); anti-ERK1/2 monoclonal rabbit (1:1000; 4695; Cell Signaling Technology, Cambridge, UK), anti-phospho-ERK1/2 (T202/Y204) monoclonal rabbit (1:1000; 4370; Cell Signaling Technology, Cambridge, UK), anti-pY (4G10; Merck Millipore; 1:1000), anti-SOCS (1:1000; 3950; Cell Signaling Technology, Cambridge, UK), anti-B2M (1:1000; ( )), ECL anti-rabbit IgG (NA934V) or anti-mouse (NA931) HRP (1:10000; GE Healthcare, Buckinghamshire, UK).

Techniques: Recombinant, DNA Methylation Assay, Expressing, RNA Sequencing Assay

Journal: Cancer Cell

Article Title: The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

doi: 10.1016/j.ccell.2018.11.018

Figure Lengend Snippet:

Article Snippet: Nitrocellulose membranes (0.45 μm Amersham Protran 10600002, GE Healthcare, Buckinghamshire, UK) were incubated with the following antibodies in the dilution as indicated (see also ): specific anti-phospho-STAT3 (Y705) polyclonal rabbit (1:1000; 9131; Cell Signaling Technology, Cambridge, UK), anti-STAT3 monoclonal mouse (1:1000; 610189; BD Biosciences, Franklin Lakes, NJ, USA) or (9139; Cell Signaling; 1:1000), anti-phospho-STAT3 (S727) polyclonal rabbit (1:1000; 9134; Cell Signaling Technology, Cambridge, UK), anti-STAT1 (rabbit; 9172; Cell Signaling; 1:1000), anti-phospho-STAT1 (Y701) monoclonal rabbit (1:1000; 9167; Cell Signaling Technology), anti-EGFL8 polyclonal rabbit (1:1000; ab58650; Abcam, Cambridge, UK), anti-phospho-EGFR (Y1068) monoclonal rabbit (1:1000; 3777; Cell Signaling Technology), anti-EGFR monoclonal rabbit (1:1000; sc-373746; Santa Cruz, Dallas, TX, USA), anti-phospho-HER2/ERBB2 (Y1221/1222) monoclonal rabbit (1:1000; 2243; Cell Signaling Technology), anti-ERBB2 monoclonal mouse (1:1000, sc-7301; Santa Cruz Biotechnology), anti-phospho-HER3/ERBB3 (Y1289) monoclonal rabbit (1:1000; 2842; Cell Signaling Technology), anti-HER3/ERBB3 monoclonal rabbit (1:1000; 12708; Cell Signaling Technology), anti-HSC70 monoclonal mouse (1:1000; sc-7298; Santa Cruz), anti-TRIM28 polyclonal rabbit (1:1000; ABE1859; Millipore); anti-ERK1/2 monoclonal rabbit (1:1000; 4695; Cell Signaling Technology, Cambridge, UK), anti-phospho-ERK1/2 (T202/Y204) monoclonal rabbit (1:1000; 4370; Cell Signaling Technology, Cambridge, UK), anti-pY (4G10; Merck Millipore; 1:1000), anti-SOCS (1:1000; 3950; Cell Signaling Technology, Cambridge, UK), anti-B2M (1:1000; ( )), ECL anti-rabbit IgG (NA934V) or anti-mouse (NA931) HRP (1:10000; GE Healthcare, Buckinghamshire, UK).

Techniques: Recombinant, Drug discovery, DNA Methylation Assay, Gene Expression, RNA Sequencing